Li X T, Hutchinson G E, Pym B A, Finch M, Hellmann K
Eur J Cancer Clin Oncol. 1983 Feb;19(2):283-7. doi: 10.1016/0277-5379(83)90428-5.
AT1727 was tested on 5 different murine tumour systems. Compared with its analogue, razoxane, AT1727 was less effective at multiple low doses against sarcoma 180 and L1210 leukaemia. A single high-dose treatment with AT1727 was, however, more active than razoxane. AT1727 inhibited the growth of the Lewis lung primary tumour and significantly reduced the number of pulmonary metastases. Although AT1727 showed a slight inhibitory effect on the growth of the B16 primary, it had no effect on the metastases.
AT1727在5种不同的小鼠肿瘤系统上进行了测试。与它的类似物丙亚胺相比,AT1727在多个低剂量时对肉瘤180和L1210白血病的疗效较差。然而,AT1727单次高剂量治疗比丙亚胺更具活性。AT1727抑制了Lewis肺癌原发肿瘤的生长,并显著减少了肺转移瘤的数量。虽然AT1727对B16原发肿瘤的生长有轻微抑制作用,但对转移瘤没有影响。